Peptides: Semaglutide — GLP-1 Receptor Agonist Science
Wilding et al. 2021 (PMID 33567185): semaglutide 2.4mg/week × 68 weeks achieved 14.9% mean body weight loss vs 2.4% placebo; 86.4% achieved ≥5% weight loss.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | A | grade | Semaglutide — multiple large Phase 3 RCTs; FDA-approved for two indications; highest evidence tier |
| Mean Body Weight Loss (STEP 1) | 14.9 | % body weight | Wilding 2021 (PMID 33567185): 2.4mg/week × 68 weeks; vs 2.4% in placebo group |
| Responder Rate ≥5% Weight Loss | 86.4 | % of participants | STEP 1: 86.4% achieved at least 5% weight loss on semaglutide vs 31.5% on placebo |
| Half-Life | 7 | days | Albumin binding via fatty acid chain extends half-life from ~2 min (endogenous GLP-1) to 7 days |
| Peptide Length | 31 | amino acids | GLP-1 analogue: 31 aa with fatty acid modification for albumin binding; endogenous GLP-1 is 30 aa |
| FDA Approvals | 2 | indications | Type 2 diabetes (Ozempic, 2017) at 0.25–2mg/week; obesity (Wegovy, 2021) at 2.4mg/week |
| Nausea Incidence | 40–50 | % of patients | Most common side effect; mitigated by 4-week dose escalation protocol; typically diminishes over time |
Why Semaglutide Belongs in Peptide Science
Semaglutide is a fully FDA-approved pharmaceutical — not a research chemical. It appears in this peptide science tower because it is, mechanistically and chemically, a peptide: a 31 amino acid GLP-1 analogue with one of the most extensively studied action profiles in modern metabolic medicine. Understanding semaglutide’s mechanism illuminates how peptide drugs are engineered, how half-life is extended through fatty acid albumin binding, and how peptide receptor agonism at specific hypothalamic targets produces profound metabolic effects.
The STEP 1 trial (Wilding et al. 2021, PMID 33567185) produced one of the largest pharmacologically-induced weight loss effect sizes ever seen in a Phase 3 obesity trial. These results set a new benchmark — one that is now being challenged only by tirzepatide, a dual GIP/GLP-1 receptor agonist.
The GLP-1 System
GLP-1 (glucagon-like peptide-1) is an incretin hormone — a gut-derived peptide released after meals that coordinates the insulin response. Endogenous GLP-1 is synthesized in intestinal L-cells and released within minutes of food ingestion. It activates GLP-1 receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion, suppresses glucagon, and acts on the hypothalamus and vagus nerve to signal satiety (Drucker 2006, PMID 16517403).
The problem with endogenous GLP-1 as a drug: its half-life is approximately 2 minutes, rapidly inactivated by dipeptidyl peptidase-4 (DPP-4). Semaglutide solves this with a fatty acid modification at position 34 that binds albumin in plasma, shielding the molecule from DPP-4 and renal clearance. The result: a half-life of approximately 7 days.
Mechanism of Weight Loss
Semaglutide’s weight loss effect is mediated through multiple simultaneous pathways:
- Hypothalamic satiety signaling: GLP-1R activation in the arcuate nucleus promotes POMC/CART (anorexigenic) neuron activity and inhibits NPY/AgRP (orexigenic) neurons
- Gastric emptying delay: slowing of gastric motility prolongs post-meal satiety
- Vagal afferent signaling: gut-to-brain satiety signal via vagal nerve GLP-1 receptors
- Insulin secretion (glucose-dependent): improves glycemic control in T2D without causing hypoglycemia at normal glucose levels
- Glucagon suppression: reduces hepatic glucose output
Efficacy Data
| Compound | Half-Life | Receptor Targets | Mean Weight Loss | Evidence Grade | Approval Status | Common Name |
|---|---|---|---|---|---|---|
| Endogenous GLP-1 | ~2 minutes | GLP-1R | N/A (native hormone) | A (mechanistic reference) | N/A | GLP-1 |
| Semaglutide (weekly) | ~7 days | GLP-1R | 14.9% (STEP 1) | A | FDA-approved (Ozempic, Wegovy) | Semaglutide |
| Semaglutide (oral) | ~1 day (oral SNAC) | GLP-1R | 9.6% (OASIS 1 trial) | A | FDA-approved (Rybelsus, Wegovy oral) | Oral semaglutide |
| Liraglutide (1.2mg) | ~13 hours | GLP-1R | 5–6% (SCALE trial) | A | FDA-approved (Victoza, Saxenda) | Liraglutide |
| Tirzepatide | ~5 days | GLP-1R + GIPR | 22.5% (SURMOUNT-1) | A | FDA-approved (Mounjaro, Zepbound) | Tirzepatide |
| Exenatide (weekly) | ~1 week | GLP-1R | 4–6% | A | FDA-approved (Bydureon) | Exenatide |
The progression from liraglutide to semaglutide to tirzepatide represents increasing weight loss efficacy — each step roughly doubling the previous generation’s effect size. Semaglutide at 2.4mg/week achieved mean weight loss of 14.9% with 86.4% of participants reaching the ≥5% threshold (clinically meaningful weight loss).
Oral Formulation
Oral semaglutide (Rybelsus at 7–14mg/day for T2D; oral Wegovy at 25mg/day for obesity) uses a formulation technology called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate). SNAC transiently increases gastric pH and permeability locally, allowing peptide absorption across the gastric mucosa. Oral bioavailability is approximately 1% relative to subcutaneous injection, which is why oral doses are roughly 10-fold higher than injectable doses.
Legal and Regulatory Status
| Jurisdiction | Status | Schedule | Notes |
|---|---|---|---|
| USA | Prescription only | Schedule Rx | FDA-approved; Ozempic (T2D), Wegovy (obesity); severe shortage 2022–2024 |
| UK | Prescription only | Schedule Rx (POM) | MHRA-approved; Ozempic and Wegovy available |
| Australia | Schedule 4 | Prescription required | TGA-approved; Ozempic approved; Wegovy approved |
| Canada | Prescription only | Schedule F | Health Canada approved for both indications |
| EU | Prescription only | Schedule Rx | EMA-approved; Ozempic and Wegovy available across EU member states |
Semaglutide is not on the WADA prohibited list for most sports. Its mechanism (appetite suppression, weight loss) does not confer athletic performance enhancement in the traditional sense, and it has no anabolic, stimulant, or masking agent properties.
Related Pages
Sources
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PMID 33567185
- Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-65. PMID 16517403
Frequently Asked Questions
Is semaglutide actually a peptide?
Yes. Semaglutide is a 31 amino acid peptide — a modified analogue of endogenous GLP-1 (glucagon-like peptide-1). It is chemically a peptide with a fatty acid side chain attached to lysine at position 34 (via a short linker), which enables albumin binding in plasma and extends the half-life from approximately 2 minutes (endogenous GLP-1) to approximately 7 days (semaglutide). This is why a weekly injection is sufficient.
How does semaglutide suppress appetite?
Semaglutide activates GLP-1 receptors in multiple locations involved in appetite regulation. Primary sites include: (1) hypothalamic arcuate nucleus — directly modulates satiety neurons (POMC/CART and NPY/AgRP pathways); (2) vagal nerve afferents in the gastrointestinal tract — slows gastric emptying and reduces food reward signaling; (3) brainstem area postrema — contributes to nausea-mediated intake reduction. The net effect is reduced caloric intake averaging 500–700 kcal/day in STEP 1 participants.
What is the difference between Ozempic (diabetes) and Wegovy (obesity)?
Both Ozempic and Wegovy contain semaglutide. Ozempic is approved for Type 2 diabetes at doses of 0.25mg to 2mg/week. Wegovy is approved for chronic weight management in adults with BMI ≥30 (or ≥27 with a weight-related comorbidity) at the higher maintenance dose of 2.4mg/week. The drug molecule is identical; the difference is the approved indication, dose range, and the regulatory pathway used to establish that indication.
What are the GI side effects and how are they managed?
Nausea is the most prevalent side effect, affecting 40–50% of patients at therapeutic doses. Vomiting occurs in approximately 25% and diarrhea in 25–30%. These effects are predominantly dose-dependent and concentrated in the dose-escalation phase. Standard protocol: start at 0.25mg/week for 4 weeks, escalate gradually to the 2.4mg/week maintenance dose over approximately 16–20 weeks. Most GI side effects diminish significantly once patients reach and stabilize at their maintenance dose.